Big Move For NTRB: Nutriband Stock Rallies 17% On Strategic Pharma Divestment Deal

2025-12-31 15:08:36

Nutriband Inc. (NTRB) made waves in the market with a solid 17.29% rally, settling at $5.63 after revealing plans to offload a 90% stake in Pocono Pharmaceutical. The buyer? EarthVision Bio, putting down $5 million in cash for the subsidiary stake.

Here’s what caught traders’ attention: by unloading most of its pharma subsidiary, Nutriband is freeing up capital to turbocharge its real priority—AVERSA Fentanyl, an abuse-deterrent transdermal opioid patch positioned as a potential game-changer in pain management. Early projections peg the drug’s annual U.S. sales potential somewhere between $80 million and $200 million, assuming it clears regulatory hurdles.

The deal structure also matters. Nutriband keeps a 10% ownership slice in the divested unit, essentially maintaining a financial hook into EarthVision Bio’s future performance while redirecting resources to core programs. That hybrid approach—part exit, part retained interest—resonated with investors seeking both liquidity and upside.

On announcement day, NTRB shares opened around $4.80, pushed higher to an intraday peak of $5.70, with a floor near $4.75. Volume spiked significantly above typical trading patterns, underscoring the market’s enthusiasm for the transaction. The stock trades on Nasdaq, and its 52-week trading range spans $2.10 to $7.40.

For pharma stocks watchers, this move signals Nutriband’s confidence in AVERSA’s commercial potential and its willingness to reshape the portfolio to bet on higher-value programs.

Disclaimer: This analysis reflects market observations and does not constitute investment advice.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.